Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Quest Diagnostics Inc (DGX) Price & Performance

BridgeBio Pharma IncTrade
Quest Diagnostics IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Quest Diagnostics Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Quest Diagnostics Inc trades at $237.5 (market cap $26.21B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.45% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIODGX
Market Cap
$16.36B$26.21B
Sector
HealthHealth
52-Week High
$90.17$238.50
52-Week Low
$47.29$173.49
Enterprise Value
$18.14B$31.97B
Dividend Yield
1.45%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX